Market Cap 97.49M
Revenue (ttm) 28.70M
Net Income (ttm) -66.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -233.28%
Debt to Equity Ratio 0.00
Volume 11,568,300
Avg Vol 5,416,006
Day's Range N/A - N/A
Shares Out 228.31M
Stochastic %K 7%
Beta 1.14
Analysts Strong Sell
Price Target $4.67

Company Profile

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influ...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 550 3500
Fax: 650 871 8580
Website: vaxart.com
Address:
170 Harbor Way, Suite 300, South San Francisco, United States
NickG88
NickG88 Oct. 25 at 9:15 PM
$VXRT As another example.. Source: Reuters https://search.app/HQTVX
0 · Reply
Garza759ify_YF
Garza759ify_YF Oct. 25 at 8:00 PM
$VXRT @Vaxylove VXRT also has potential in cancer pill pipeline.
0 · Reply
Garza759ify_YF
Garza759ify_YF Oct. 25 at 7:57 PM
$VXRT We will get through all the struggles and obstacles by kicking out VXRT board and nominating our own VXRT board members. VXRT market maker also must be kicked out. Partnerships are homeruns for VXRT. We need concenerd VXRT investor group to get to the finish line.
0 · Reply
Garza759ify_YF
Garza759ify_YF Oct. 25 at 7:48 PM
0 · Reply
Vaxylove
Vaxylove Oct. 25 at 7:32 PM
$VXRT Blow The Doors Off The tweet below is from February 2024, nearly two years ago. Our original construct was durable and cross-reactive to all tested CoV-2 variants. And now we have a next gen that is 40 - 100x more immunogenic. The 400-subject data could blow the door off of this play, even if the masses don't believe Covid is a thing anymore. If data is positive, it could: 1. Unlock global funding. 2. Open new partnerships (pharma, government, global health orgs) for additional indications. 3. Improve investor sentiment, leading to better access to capital, higher valuations, and ability to fund other programs. 4. Accelerate regulatory discussions with the FDA, and/or seeking conditional approvals/fast track if the data are compelling. 5. Give us platform credibility and real-world validation, which helps with licensing and global distribution deals, especially in LMIC's where cold-chain is a barrier. I disagree with those who say we'll be lucky to get to $3 - $5 in a few years. The way I see it, we don't have to wait to go to market to make some serious coin. Once we land one major partnership, perception will change and the dominos will start falling: Additional funding, partnerships, licensing deals, global attention. Imagine multiple governments signing on for Noro. And Gates buying hundreds of millions of doses for Gavi. And this cycle will continue. The best part is we won't have to push it. Every year, institutions and governments will simply reorder.
5 · Reply
Faithless
Faithless Oct. 25 at 7:16 PM
$VXRT @ndouglas48 thoughts on the close this week?
0 · Reply
gekkosbutt
gekkosbutt Oct. 25 at 7:03 PM
$VXRT HARPUA.........NO ON RS FOREVER!!! VERY HAPPY WITH MY CHOICE TO VOTE NO AND WILL CONTINUE TO DO SO.
2 · Reply
HJAC
HJAC Oct. 25 at 7:02 PM
$VXRT Posted on LinkedIn
1 · Reply
Harpua97
Harpua97 Oct. 25 at 4:55 PM
$VXRT @AnilDK79 If Covid vaccine is approved and gets to market, I’d estimate market cap rising to between $1B - $3B, with the higher end being if it looks like Noro is headed in the right direction too. But again, that is likely 3-5 years out. Here’s why: - It will be another 12 months until we have results from this P2B trial. - Next is a P3, which from design to enrollment to completion will likely be another 18 months. - Then it’s 1-3 months of statistical analysis by Vaxart. - Then it’s ~2 months for FDA to review a BLA - After that, the FDA review clock starts. If designated as priority, that’s ~6 months. Otherwise closer to 10 months. - Finally, the vaccine advisory committee meets to review, which could add up to another 1-2 months. - And then, if all goes well, we get approval and can begin manufacturing and distribution. So when you add it up, it’s 40-48 months from now when we would likely go to market, and that’s if there are no hiccups or delays. If no dilution happens between now and then (not likely, but we can hope), a $1B- $3B valuation would mean a share price of $4.50 - $13. I’ve never said it’s impossible to get there, just that guys like @SackLo need to get real about how long it’s going to take and that no matter who is at the helm, he’s not going to see 10x share price by end of Q1.
1 · Reply
Harpua97
Harpua97 Oct. 25 at 4:32 PM
$VXRT @MaxToMax22 Sure I can! Look, I’m doing it right now! Shareholders made a big mistake rejecting the r/s. But what’s done is done. And again, the no voters won fair and square, and I accept the defeat. The topic only came up because folks here continue to talk about achieving insane share prices in the near-term, and that is highly unlikely from OTC. This message board spent a lot of time talking about “save our shares,” etc, but not much time considering the downside of OTC. It’s going to be a wake up call for a lot of people when they see that a partnership doesn’t suddenly 10x the share price. Could’ve happened from Nasdaq because of institutional buyers and retail FOMO, but neither of those work from OTC. I still believe we can see material share price growth, just going to take years to happen from OTC.
1 · Reply
Latest News on VXRT
Vaxart Appoints W. Mark Watson as Lead Independent Director

Sep 17, 2025, 4:05 PM EDT - 5 weeks ago

Vaxart Appoints W. Mark Watson as Lead Independent Director


Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 9:01 PM EDT - 2 months ago

Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript


US orders Vaxart to stop COVID-19 trial amid mRNA wind down

Aug 13, 2025, 5:25 PM EDT - 2 months ago

US orders Vaxart to stop COVID-19 trial amid mRNA wind down


Vaxart Announces Adjournment of Annual Meeting of Stockholders

Jun 2, 2025, 4:20 PM EDT - 5 months ago

Vaxart Announces Adjournment of Annual Meeting of Stockholders


Vaxart, Inc. (VXRT) Q1 2025 Earnings Call Transcript

May 13, 2025, 8:43 PM EDT - 5 months ago

Vaxart, Inc. (VXRT) Q1 2025 Earnings Call Transcript


Vaxart Appoints Jeroen Grasman as Chief Financial Officer

May 13, 2025, 4:01 PM EDT - 5 months ago

Vaxart Appoints Jeroen Grasman as Chief Financial Officer


Vaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 6:25 PM EDT - 7 months ago

Vaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript


Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 6:19 PM EST - 1 year ago

Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript


Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 8:51 PM EDT - 1 year ago

Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript


Vaxart Provides Business Update

Jun 17, 2024, 4:05 PM EDT - 1 year ago

Vaxart Provides Business Update


Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript

May 13, 2024, 5:49 PM EDT - 1 year ago

Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript


NickG88
NickG88 Oct. 25 at 9:15 PM
$VXRT As another example.. Source: Reuters https://search.app/HQTVX
0 · Reply
Garza759ify_YF
Garza759ify_YF Oct. 25 at 8:00 PM
$VXRT @Vaxylove VXRT also has potential in cancer pill pipeline.
0 · Reply
Garza759ify_YF
Garza759ify_YF Oct. 25 at 7:57 PM
$VXRT We will get through all the struggles and obstacles by kicking out VXRT board and nominating our own VXRT board members. VXRT market maker also must be kicked out. Partnerships are homeruns for VXRT. We need concenerd VXRT investor group to get to the finish line.
0 · Reply
Garza759ify_YF
Garza759ify_YF Oct. 25 at 7:48 PM
0 · Reply
Vaxylove
Vaxylove Oct. 25 at 7:32 PM
$VXRT Blow The Doors Off The tweet below is from February 2024, nearly two years ago. Our original construct was durable and cross-reactive to all tested CoV-2 variants. And now we have a next gen that is 40 - 100x more immunogenic. The 400-subject data could blow the door off of this play, even if the masses don't believe Covid is a thing anymore. If data is positive, it could: 1. Unlock global funding. 2. Open new partnerships (pharma, government, global health orgs) for additional indications. 3. Improve investor sentiment, leading to better access to capital, higher valuations, and ability to fund other programs. 4. Accelerate regulatory discussions with the FDA, and/or seeking conditional approvals/fast track if the data are compelling. 5. Give us platform credibility and real-world validation, which helps with licensing and global distribution deals, especially in LMIC's where cold-chain is a barrier. I disagree with those who say we'll be lucky to get to $3 - $5 in a few years. The way I see it, we don't have to wait to go to market to make some serious coin. Once we land one major partnership, perception will change and the dominos will start falling: Additional funding, partnerships, licensing deals, global attention. Imagine multiple governments signing on for Noro. And Gates buying hundreds of millions of doses for Gavi. And this cycle will continue. The best part is we won't have to push it. Every year, institutions and governments will simply reorder.
5 · Reply
Faithless
Faithless Oct. 25 at 7:16 PM
$VXRT @ndouglas48 thoughts on the close this week?
0 · Reply
gekkosbutt
gekkosbutt Oct. 25 at 7:03 PM
$VXRT HARPUA.........NO ON RS FOREVER!!! VERY HAPPY WITH MY CHOICE TO VOTE NO AND WILL CONTINUE TO DO SO.
2 · Reply
HJAC
HJAC Oct. 25 at 7:02 PM
$VXRT Posted on LinkedIn
1 · Reply
Harpua97
Harpua97 Oct. 25 at 4:55 PM
$VXRT @AnilDK79 If Covid vaccine is approved and gets to market, I’d estimate market cap rising to between $1B - $3B, with the higher end being if it looks like Noro is headed in the right direction too. But again, that is likely 3-5 years out. Here’s why: - It will be another 12 months until we have results from this P2B trial. - Next is a P3, which from design to enrollment to completion will likely be another 18 months. - Then it’s 1-3 months of statistical analysis by Vaxart. - Then it’s ~2 months for FDA to review a BLA - After that, the FDA review clock starts. If designated as priority, that’s ~6 months. Otherwise closer to 10 months. - Finally, the vaccine advisory committee meets to review, which could add up to another 1-2 months. - And then, if all goes well, we get approval and can begin manufacturing and distribution. So when you add it up, it’s 40-48 months from now when we would likely go to market, and that’s if there are no hiccups or delays. If no dilution happens between now and then (not likely, but we can hope), a $1B- $3B valuation would mean a share price of $4.50 - $13. I’ve never said it’s impossible to get there, just that guys like @SackLo need to get real about how long it’s going to take and that no matter who is at the helm, he’s not going to see 10x share price by end of Q1.
1 · Reply
Harpua97
Harpua97 Oct. 25 at 4:32 PM
$VXRT @MaxToMax22 Sure I can! Look, I’m doing it right now! Shareholders made a big mistake rejecting the r/s. But what’s done is done. And again, the no voters won fair and square, and I accept the defeat. The topic only came up because folks here continue to talk about achieving insane share prices in the near-term, and that is highly unlikely from OTC. This message board spent a lot of time talking about “save our shares,” etc, but not much time considering the downside of OTC. It’s going to be a wake up call for a lot of people when they see that a partnership doesn’t suddenly 10x the share price. Could’ve happened from Nasdaq because of institutional buyers and retail FOMO, but neither of those work from OTC. I still believe we can see material share price growth, just going to take years to happen from OTC.
1 · Reply
WALTERPAYTON34
WALTERPAYTON34 Oct. 25 at 3:42 PM
$VXRT if the science is proven Vaxart could trade on Mars and it will not matter
0 · Reply
TripleLinde
TripleLinde Oct. 25 at 2:46 PM
$VXRT Interesting article on the benefits, and potential pitfalls, of platform development. https://www.sciencedirect.com/science/article/pii/S0277953625010184?via%3Dihub
2 · Reply
HarvnDean10
HarvnDean10 Oct. 25 at 2:35 PM
$VXRT Fartua is still hung up on the R/S claiming it works in the long run. This guy has zero credentials and is constantly wrong in his opinions. Please stay off the airwaves Fartua as you are wasting our time. Simple math will tell you (along with countless historical examples) that most all R/S make the shorts money....not the longs, especially when there is 95% dilution. Good grief, what a loser!
1 · Reply
HJAC
HJAC Oct. 25 at 2:27 PM
$VXRT Can someone ask BGirl to unblock me. We’re all on the same side here. Thanks in advance.
1 · Reply
TripleLinde
TripleLinde Oct. 25 at 12:24 PM
$VXRT New study funded by NIH published by Stephanie Langel. (Good news that NIH is funding studies on oral vaccines) I was curious about what I percieved to be conflicting findings between Vaxart's lactating moms study, and Langel's study and this is what I got back from Chat: 1. Vaxart’s lactation study supports biologic plausibility (more milk IgA/functional antibodies) for passive protection against norovirus in nursing infants. 2. The EMBO/“Langel” discussion implies that if an infant oral norovirus vaccine were used in the future, high maternal antibodies could reduce infant vaccine take—a classic tradeoff that vaccinologists manage with dose/formulation/timing. (WHO/CDC RSV guidance shows how maternal immunization and monoclonal antibodies are timed to avoid such issues.) https://www.embopress.org/doi/full/10.1038/s44318-025-00583-1
4 · Reply
Garza759ify_YF
Garza759ify_YF Oct. 25 at 9:23 AM
$VXRT Reverse split will never work in any situation.
2 · Reply
MaxToMax22
MaxToMax22 Oct. 25 at 3:44 AM
R/S The R/S is definitely advantageous. However, just a year ago, $VXRT received $400 million in support from BARDA. The SP was at 1.80 and is likely to continue its upward trend. Why was the dilution at 0.80? If they had waited a week, the SP would have been at $5. So, the company had the potential to raise more capital. The R/S would never have been necessary. You can't blame investors for rejecting the R/S.
2 · Reply
RoutineMidnight5779
RoutineMidnight5779 Oct. 25 at 3:24 AM
$VXRT Does this mean we should have 400 cohort results soon?
2 · Reply
RoutineMidnight5779
RoutineMidnight5779 Oct. 25 at 3:22 AM
$VXRT good to see this again 🙃
0 · Reply
SackLo
SackLo Oct. 25 at 3:18 AM
$VXRT Seems replying to posts needs a reshare to shout louder now !! All about trying to control the narrative, this guy is a dream case study for human behaviour 🤣 Wishful thinking doesn’t make for a RS strategy either does it ? With that now failed, and the spotlight now really on, let’s really play down expectations. We’ve heard the excuses, the comparisons to suit, the pitching of low ball success and timelines way out in to the horizon. Wishful thinking doesn’t make for SH believing the success and timelines pitched so low, with the same agenda to create restlessness and division. Funny how years of weekly update around % drifting to extraordinary levels now attracts a response ?
1 · Reply
RoutineMidnight5779
RoutineMidnight5779 Oct. 25 at 3:09 AM
$VXRT just on this alone, CEO should be removed. @SoldDaPopinski
1 · Reply
amessagefromtheodd
amessagefromtheodd Oct. 25 at 12:15 AM
$VXRT Based on Vaxart's announcements from June 2024, the company did an underwritten offering for $40 million on the same day it announced receiving a BARDA award valued at up to $453 million. 80 cent…
1 · Reply